Yellow fever vaccination: important new guidance for health professionals

Public Health England has published guidance for health professionals managing clinical incidents or adverse vaccine associated events related to yellow fever vaccination
Yellow fever vaccination: important new guidance for health professionals

On 27 January 2020, Public Health England published guidance [1] on the recommended immediate management of:

  • Persons who are well or unwell following inadvertent administration of yellow fever (YF) vaccine (i.e. where there was a contraindication to yellow fever vaccination).
  • Persons experiencing a YF vaccine associated severe adverse event.

This guidance is for health professionals working in Yellow Fever Vaccination Centres (YFVCs) and those providing medical care to persons who are well or unwell following inadvertent administration of the vaccine, or those who are vaccinated appropriately, but who develop a vaccine associated adverse event following vaccination.

As well as providing a background to the recommendations, included in the guidance are:

  • A flow chart of actions to be taken.
  • A surveillance form on which to document an incident or severe adverse event (including medical and travel history).
  • Definition of roles and responsibilities of the reporting and supervising clinical teams.

Health professionals working in UKYFVCs should read this guidance in its entirety, ensure the information is disseminated widely to the clinical team and applied in clinical practice.

Travellers who receive YF vaccine should be informed by the administering health professional about the early signs and symptoms of YF vaccine side effects and need to urgently seek medical attention if serious side effects are suspected [2].

The full guidance is available from Public Health England:


Search by


Explore more

Marburg virus disease in Ethiopia

On 26 January 2026, the Ministry of Health of Ethiopia declared the end of the Marburg virus disease outbreak

Updated: 05 February 2026

ABTA Destinations to Watch report published

ABTA has launched its Destinations to Watch report for 2026

Updated: 03 February 2026

Mefloquine shortage

Shortage of 250mg mefloquine (Lariam) antimalarial tablets in the United Kingdom (UK) until the end of March 2026

Updated: 30 January 2026

NaTHNaC Telephone Advice Line for health professionals

Additional advice line sessions are planned, starting in January 2026

Updated: 21 January 2026

Country Information updates: Japanese encephalitis vaccine recommendations

NaTHNaC has reviewed and updated the Japanese encephalitis (JE) country-specific information and vaccine recommendations

Updated: 19 January 2026